$EGRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in EAGLE PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in EAGLE PHARMACEUTICALS, INC.. Get notifications about new insider transactions in EAGLE PHARMACEUTICALS, INC. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 29 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.01 | 1,600 | 132,816 | 23,274 | 24.9 K to 23.3 K (-6.43 %) |
Mar 29 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.00 | 1,300 | 107,900 | 24,874 | 26.2 K to 24.9 K (-4.97 %) |
Mar 29 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.01 | 500 | 41,505 | 6,777 | 7.3 K to 6.8 K (-6.87 %) |
Mar 29 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.00 | 400 | 33,200 | 7,277 | 7.7 K to 7.3 K (-5.21 %) |
Mar 29 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.01 | 58,755 | 4,877,253 | 3,675,419 | 3.7 M to 3.7 M (-1.57 %) |
Mar 29 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.02 | 6,182 | 513,230 | 3,734,174 | 3.7 M to 3.7 M (-0.17 %) |
Mar 29 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.00 | 37,731 | 3,131,673 | 3,740,356 | 3.8 M to 3.7 M (-1.00 %) |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 12.63 | 5,000 | 63,150 | 15,000 | |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 12.67 | 2,025 | 25,657 | 4,850 | |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 12.67 | 2,077 | 26,316 | 6,875 | |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 4.42 | 5,023 | 22,202 | 457 | |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 82.06 | 7,025 | 576,489 | 0 | 7 K to 0 (-100.00 %) |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 12.63 | 5,000 | 63,150 | 7,025 | 2 K to 7 K (+246.91 %) |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 12.67 | 2,025 | 25,657 | 2,025 | 0 to 2 K |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 80.09 | 7,100 | 568,641 | 0 | 7.1 K to 0 (-100.00 %) |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 12.67 | 2,077 | 26,316 | 7,100 | 5 K to 7.1 K (+41.35 %) |
Mar 24 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 4.42 | 5,023 | 22,202 | 5,023 | 0 to 5 K |
Mar 23 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.01 | 700 | 58,107 | 3,778,087 | 3.8 M to 3.8 M (-0.02 %) |
Mar 23 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 83.10 | 500 | 41,550 | 3,778,787 | 3.8 M to 3.8 M (-0.01 %) |
Mar 22 2017 | EGRX | EAGLE PHARMACEUTIC ... | Edlin Richard A. | Director | Buy | P | 79.44 | 6,000 | 476,640 | 29,400 | 23.4 K to 29.4 K (+25.64 %) |
Mar 21 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 83.98 | 61 | 5,123 | 511 | 450 to 511 (+13.56 %) |
Mar 21 2017 | EGRX | EAGLE PHARMACEUTIC ... | Edlin Richard A. | Director | Option Exercise | A | 81.27 | 10,000 | 812,700 | 10,000 | |
Mar 20 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 82.10 | 51,883 | 4,259,594 | 3,779,287 | 3.8 M to 3.8 M (-1.35 %) |
Mar 20 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 82.01 | 38,997 | 3,198,144 | 3,831,170 | 3.9 M to 3.8 M (-1.01 %) |
Mar 20 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 82.08 | 9,120 | 748,570 | 3,870,167 | 3.9 M to 3.9 M (-0.24 %) |
Mar 10 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 77.84 | 450 | 35,028 | 450 | 0 to 450 |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | RIGGS DAVID E | Chief Financial Off ... | Option Exercise | A | 84.92 | 40,000 | 3,396,800 | 40,000 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Graves Michael | Director | Option Exercise | A | 84.92 | 10,000 | 849,200 | 10,000 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Glenning Robert | Director | Option Exercise | A | 84.92 | 10,000 | 849,200 | 10,000 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Option Exercise | A | 84.92 | 10,000 | 849,200 | 10,000 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Option Exercise | A | 84.92 | 10,000 | 849,200 | 10,000 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | CEO | Option Exercise | A | 84.92 | 200,900 | 17,060,428 | 200,900 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | A | 84.92 | 42,000 | 3,566,640 | 42,000 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Braunstein Douglas L | Director | Option Exercise | A | 84.92 | 10,000 | 849,200 | 10,000 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 84.92 | 90,000 | 7,642,800 | 90,000 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Hepner Adrian | EVP and Chief Medic ... | Option Exercise | A | 84.92 | 67,200 | 5,706,624 | 67,200 | |
Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 85.16 | 65,114 | 5,545,108 | 3,879,287 | 3.9 M to 3.9 M (-1.65 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 46.09 | 5,127 | 236,303 | 53,464 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 46.09 | 5,126 | 236,257 | 58,591 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 46.09 | 7,569 | 348,855 | 63,717 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 12.63 | 2,683 | 33,886 | 20,000 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 12.63 | 10,000 | 126,300 | 22,683 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 12.63 | 7,317 | 92,414 | 32,683 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 12.67 | 2,683 | 33,994 | 8,952 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 12.67 | 6,270 | 79,441 | 11,635 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 4.42 | 3,730 | 16,487 | 5,480 | |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 78.61 | 5,127 | 403,018 | 0 | 5.1 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 46.09 | 5,127 | 236,303 | 5,127 | 0 to 5.1 K |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 76.78 | 5,126 | 393,571 | 0 | 5.1 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 46.09 | 5,126 | 236,257 | 5,126 | 0 to 5.1 K |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 77.17 | 7,569 | 584,135 | 0 | 7.6 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 46.09 | 7,569 | 348,855 | 7,569 | 0 to 7.6 K |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 77.17 | 2,683 | 207,060 | 0 | 2.7 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 12.63 | 2,683 | 33,886 | 2,683 | 0 to 2.7 K |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 76.69 | 10,000 | 766,876 | 0 | 10 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 12.63 | 10,000 | 126,300 | 10,000 | 0 to 10 K |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 75.61 | 7,317 | 553,213 | 0 | 7.3 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 12.63 | 7,317 | 92,414 | 7,317 | 0 to 7.3 K |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 75.61 | 2,683 | 202,853 | 0 | 2.7 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 12.67 | 2,683 | 33,994 | 2,683 | 0 to 2.7 K |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 74.79 | 6,270 | 468,931 | 0 | 6.3 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 12.67 | 6,270 | 79,441 | 6,270 | 0 to 6.3 K |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 74.79 | 3,730 | 278,965 | 0 | 3.7 K to 0 (-100.00 %) |
Jan 04 2017 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 4.42 | 3,730 | 16,487 | 3,730 | 0 to 3.7 K |
Dec 15 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 4.42 | 10,000 | 44,200 | 9,210 | |
Dec 15 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 73.62 | 10,000 | 736,163 | 0 | 10 K to 0 (-100.00 %) |
Dec 15 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 4.42 | 10,000 | 44,200 | 10,000 | 0 to 10 K |
Dec 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Sell | S | 75.00 | 8,700 | 652,500 | 13,324 | 22 K to 13.3 K (-39.50 %) |
Dec 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Sell | S | 75.07 | 1,300 | 97,591 | 22,024 | 23.3 K to 22 K (-5.57 %) |
Dec 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | RATOFF STEVEN B | Director | Buy | P | 12.79 | 3,950 | 50,521 | 23,324 | 19.4 K to 23.3 K (+20.39 %) |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 4.42 | 1,307 | 5,777 | 19,210 | |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 8.78 | 2,530 | 22,213 | 0 | |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 8.78 | 1,950 | 17,121 | 0 | |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Option Exercise | M | 8.78 | 200 | 1,756 | 2,530 | |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 80.00 | 1,307 | 104,560 | 0 | 1.3 K to 0 (-100.00 %) |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 4.42 | 1,307 | 5,777 | 1,307 | 0 to 1.3 K |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 80.00 | 2,530 | 202,400 | 0 | 2.5 K to 0 (-100.00 %) |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 8.78 | 2,530 | 22,213 | 2,530 | 0 to 2.5 K |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 80.00 | 1,950 | 156,000 | 0 | 2 K to 0 (-100.00 %) |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 8.78 | 1,950 | 17,121 | 1,950 | 0 to 2 K |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Sell | S | 80.00 | 200 | 16,000 | 0 | 200 to 0 (-100.00 %) |
Dec 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Krill Steven L. | EVP & Chief Scienti ... | Buy | M | 8.78 | 200 | 1,756 | 200 | 0 to 200 |
Nov 30 2016 | EGRX | EAGLE PHARMACEUTIC ... | FLAUM SANDER A | Director | Sell | S | 78.66 | 5,000 | 393,300 | 11,374 | 16.4 K to 11.4 K (-30.54 %) |
Nov 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 85.00 | 15,551 | 1,321,835 | 3,944,401 | 4 M to 3.9 M (-0.39 %) |
Nov 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 85.00 | 1,300 | 110,500 | 26,174 | 27.5 K to 26.2 K (-4.73 %) |
Nov 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 85.00 | 300 | 25,500 | 7,677 | 8 K to 7.7 K (-3.76 %) |
Nov 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 87.05 | 1,700 | 147,985 | 3,959,952 | 4 M to 4 M (-0.04 %) |
Nov 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 86.06 | 100 | 8,606 | 3,961,652 | 4 M to 4 M (0.00 %) |
Nov 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 86.00 | 167 | 14,362 | 3,961,752 | 4 M to 4 M (0.00 %) |
Nov 14 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 85.10 | 15,368 | 1,307,817 | 3,961,919 | 4 M to 4 M (-0.39 %) |
Nov 09 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 80.09 | 102,919 | 8,242,783 | 3,977,287 | 4.1 M to 4 M (-2.52 %) |
Nov 09 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 79.24 | 19,581 | 1,551,598 | 4,080,206 | 4.1 M to 4.1 M (-0.48 %) |
Nov 09 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 78.23 | 4,200 | 328,566 | 4,099,787 | 4.1 M to 4.1 M (-0.10 %) |
Nov 09 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 77.13 | 9,030 | 696,484 | 4,103,987 | 4.1 M to 4.1 M (-0.22 %) |
Nov 09 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 76.49 | 11,690 | 894,168 | 4,113,017 | 4.1 M to 4.1 M (-0.28 %) |
Nov 09 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 75.70 | 1,380 | 104,466 | 4,124,707 | 4.1 M to 4.1 M (-0.03 %) |
Nov 09 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 75.39 | 5,030 | 379,212 | 4,126,087 | 4.1 M to 4.1 M (-0.12 %) |
Nov 04 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 75.00 | 46,170 | 3,462,750 | 4,181,446 | 4.2 M to 4.2 M (-1.09 %) |
Nov 04 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 70.00 | 2,100 | 147,000 | 27,474 | 29.6 K to 27.5 K (-7.10 %) |
Nov 04 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 70.00 | 800 | 56,000 | 7,977 | 8.8 K to 8 K (-9.11 %) |
Nov 04 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 70.41 | 50,329 | 3,543,665 | 4,177,287 | 4.2 M to 4.2 M (-1.19 %) |
Nov 04 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 70.00 | 146,371 | 10,245,970 | 4,227,616 | 4.4 M to 4.2 M (-3.35 %) |
Oct 04 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 70.06 | 22,100 | 1,548,326 | 4,373,987 | 4.4 M to 4.4 M (-0.50 %) |
Sep 30 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 70.04 | 77,900 | 5,456,116 | 4,396,087 | 4.5 M to 4.4 M (-1.74 %) |
Sep 23 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 66.17 | 654 | 43,275 | 29,574 | 30.2 K to 29.6 K (-2.16 %) |
Sep 23 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 66.17 | 194 | 12,837 | 8,777 | 9 K to 8.8 K (-2.16 %) |
Sep 23 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 67.24 | 1,798 | 120,898 | 4,473,987 | 4.5 M to 4.5 M (-0.04 %) |
Sep 23 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 66.15 | 97,149 | 6,426,406 | 4,475,785 | 4.6 M to 4.5 M (-2.12 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.33 | 224 | 13,962 | 30,228 | 30.5 K to 30.2 K (-0.74 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.33 | 66 | 4,114 | 8,971 | 9 K to 9 K (-0.73 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.33 | 33,796 | 2,106,505 | 4,572,934 | 4.6 M to 4.6 M (-0.73 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.26 | 75 | 4,670 | 30,452 | 30.5 K to 30.5 K (-0.25 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.26 | 22 | 1,370 | 9,037 | 9.1 K to 9 K (-0.24 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.26 | 11,345 | 706,340 | 4,606,730 | 4.6 M to 4.6 M (-0.25 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.83 | 166 | 10,430 | 30,527 | 30.7 K to 30.5 K (-0.54 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.83 | 49 | 3,079 | 9,059 | 9.1 K to 9.1 K (-0.54 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 63.25 | 12,224 | 773,168 | 4,618,075 | 4.6 M to 4.6 M (-0.26 %) |
Sep 08 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.45 | 12,958 | 809,227 | 4,630,299 | 4.6 M to 4.6 M (-0.28 %) |
Aug 25 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.78 | 76 | 4,771 | 30,693 | 30.8 K to 30.7 K (-0.25 %) |
Aug 25 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.78 | 23 | 1,444 | 9,108 | 9.1 K to 9.1 K (-0.25 %) |
Aug 25 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.78 | 11,506 | 722,347 | 4,643,257 | 4.7 M to 4.6 M (-0.25 %) |
Aug 25 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 63.12 | 113 | 7,133 | 30,769 | 30.9 K to 30.8 K (-0.37 %) |
Aug 25 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 63.12 | 34 | 2,146 | 9,131 | 9.2 K to 9.1 K (-0.37 %) |
Aug 25 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 63.14 | 17,118 | 1,080,831 | 4,654,763 | 4.7 M to 4.7 M (-0.37 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 61.00 | 96 | 5,856 | 30,882 | 31 K to 30.9 K (-0.31 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 61.00 | 29 | 1,769 | 5,387 | 5.4 K to 5.4 K (-0.54 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 61.19 | 9,848 | 602,599 | 4,671,779 | 4.7 M to 4.7 M (-0.21 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 60.85 | 4,723 | 287,395 | 4,681,627 | 4.7 M to 4.7 M (-0.10 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 60.78 | 394 | 23,947 | 30,978 | 31.4 K to 31 K (-1.26 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 60.78 | 117 | 7,111 | 5,416 | 5.5 K to 5.4 K (-2.11 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 62.21 | 31,599 | 1,965,774 | 4,686,350 | 4.7 M to 4.7 M (-0.67 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 61.65 | 11,770 | 725,621 | 4,717,949 | 4.7 M to 4.7 M (-0.25 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 60.66 | 16,270 | 986,938 | 4,729,719 | 4.7 M to 4.7 M (-0.34 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 60.70 | 163 | 9,894 | 31,372 | 31.5 K to 31.4 K (-0.52 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 60.70 | 49 | 2,974 | 5,533 | 5.6 K to 5.5 K (-0.88 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 61.31 | 8,070 | 494,772 | 4,745,989 | 4.8 M to 4.7 M (-0.17 %) |
Aug 17 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Investments IV, L.P. | 10% Owner | Sell | S | 60.51 | 16,667 | 1,008,520 | 4,754,059 | 4.8 M to 4.8 M (-0.35 %) |
Aug 04 2016 | EGRX | EAGLE PHARMACEUTIC ... | Graves Michael | Director | Option Exercise | A | 46.66 | 15,000 | 699,900 | 15,000 | |
Jul 06 2016 | EGRX | EAGLE PHARMACEUTIC ... | Braunstein Douglas L | Director | Option Exercise | A | 41.01 | 10,000 | 410,100 | 10,000 | |
Jul 06 2016 | EGRX | EAGLE PHARMACEUTIC ... | Glenning Robert | Director | Option Exercise | A | 41.01 | 10,000 | 410,100 | 10,000 | |
Jun 30 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Financial LLC | 10% Owner | Sell | J | 0.00 | 9,903 | 0 | 5,582 | 15.5 K to 5.6 K (-63.95 %) |
May 24 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Management LLC | 10% Owner | Sell | J | 0.00 | 9,360 | 0 | 9,360 | 18.7 K to 9.4 K (-50.00 %) |
May 24 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Management LLC | 10% Owner | Sell | J | 0.00 | 4,770,828 | 0 | 4,770,828 | 9.5 M to 4.8 M (-50.00 %) |
May 16 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Management LLC | 10% Owner | Sell | S | 40.92 | 13,980 | 572,062 | 41,081 | 55.1 K to 41.1 K (-25.39 %) |
May 16 2016 | EGRX | EAGLE PHARMACEUTIC ... | ProQuest Management LLC | 10% Owner | Sell | S | 40.00 | 4,000 | 160,000 | 55,061 | 59.1 K to 55.1 K (-6.77 %) |
Apr 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 40.63 | 30,765 | 1,249,982 | 1,369,946 | 1.4 M to 1.4 M (-2.20 %) |
Mar 16 2016 | EGRX | EAGLE PHARMACEUTIC ... | Graves Michael | Director | Buy | P | 56.73 | 1,000 | 56,730 | 1,000 | 0 to 1,000 |
Mar 03 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 63.52 | 11,978 | 760,843 | 1,400,711 | 1.4 M to 1.4 M (-0.85 %) |
Mar 03 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 62.70 | 7,802 | 489,185 | 1,412,689 | 1.4 M to 1.4 M (-0.55 %) |
Feb 02 2016 | EGRX | EAGLE PHARMACEUTIC ... | Tarriff Scott | President and CEO | Sell | S | 71.84 | 1,702 | 122,272 | 1,420,491 | 1.4 M to 1.4 M (-0.12 %) |